FDA issues complete response letter for Pfizer’s tafamidis meglumine New Drug Application
18 June 2012 | By Pfizer
Tafamidis is a novel, investigational medication for the treatment of TTR-FAP...
List view / Grid view
18 June 2012 | By Pfizer
Tafamidis is a novel, investigational medication for the treatment of TTR-FAP...
15 June 2012 | By Pfizer
Pfizer has announced the launch of a new Web site, “Campaign Against Migraine”, to help migraine sufferers across the country...
25 May 2012 | By Pfizer
The CHMP of the EMA has adopted a positive opinion regarding the marketing authorization of axitinib in the European Union (EU)...
23 May 2012 | By Pfizer
Olivier will succeed David Simmons...
22 May 2012 | By Pfizer
View webcast of a presentation by Pfizer’s oncology leadership team...
18 May 2012 | By Pfizer
Results of studies on Lyrica® announced...
15 May 2012 | By Pfizer
Pfizer Inc announced that the Phase 3 INTORSECT study...
14 May 2012 | By Pfizer
New data will be presented on targeted cancer treatments from the Pfizer Oncology portfolio across three key therapeutic categories...
14 May 2012 | By University of Dundee
The consortium includes six companies & will provide core support of £14.4 million...
10 May 2012 | By Pfizer
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with David Simmons...
9 May 2012 | By Pfizer
“We are pleased with the Committee’s positive evaluation..."
7 May 2012 | By Pfizer
Pfizer announced new data presented at the 165th Annual Meeting of the APA...
4 May 2012 | By Pfizer
Pfizer has stopped a Phase 3 clinical trial of Lyrica in patients with neuropathic pain...
4 May 2012 | By Pfizer
Pfizer announced that a Phase 3 randomized withdrawal design study for Lyrica in patients...
1 May 2012 | By Pfizer
The U.S. FDA has approved ELELYSO™...